IDTechEx: Investment Sought for 3D Printed Hearts

BIOLIFE4D announced it filed a $50 million initial public offering with the Securities and Exchange Commission (SEC) under Regulation A+ rules, allowing everyday investors to help the company bring its groundbreaking cardiac tissue regeneration and organ replacement process to market.

Chicago-based BIOLIFE4D is a pioneering biotech company focused on leveraging advances in life sciences and tissue engineering to 3D bioprint a viable human heart suitable for transplant. The company plans to use proceeds from the offering to bolster working capital and fund key corporate initiatives including hiring additional employees to supplement its world-class science advisory team, procuring laboratory space, and developing and licensing related technology.

Read more here: BIOLIFE4D


Build a Heart. Save a life.

Scroll Up